Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ricardo A. Loaiza
Institutions:
Pontificia Universidad Católica de Chile,
Millennium Institute on Immunology and Immunotherapy
Observed institutions:
Pontificia Universidad Católica de Chile,
Millennium Institute on Immunology and Immunotherapy
ORCID:
0000-0002-8449-3396
Observed ORCID:
0000-0002-8449-3396
OpenAlex ID:
A5034528189
Involvement of trained immunity during autoimmune responses
2022
·
Valentina P. Mora
, Ricardo A. Loaiza
, et al.
·
Journal of Autoimmunity
·
52
Advancement in the development of mRNA ‐based vaccines for respiratory viruses
2024
·
Tays Troncoso‐Bravo
, Mario A. Ramírez
, et al.
·
Immunology
·
25
PDF
Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity
2024
·
Mario A. Ramírez
, Ricardo A. Loaiza
, et al.
·
Vaccine
·
6
A molecular perspective for the development of antibodies against the human respiratory syncytial virus
2023
·
Ricardo A. Loaiza
, Robinson A. Ramírez
, et al.
·
Antiviral Research
·
5
PDF
Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection
2024
·
Ricardo A. Loaiza
, Mónica A. Farías
, et al.
·
Expert Review of Anti-infective Therapy
·
3
Current and emerging pharmacological treatments for respiratory syncytial virus infection in high-risk infants
2023
·
Jorge A. Soto
, Ricardo A. Loaiza
, et al.
·
Expert Opinion on Pharmacotherapy
·
2
Long-term stability of the GMP-compliant recombinant BCG vaccine against human RSV under quality control analyses
2026
·
Tays Troncoso-Bravo
, Daniela B. Rivera
, et al.
·
iScience
Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody
2026
·
Mónica A. Farías
, Catalina A. Andrade
, et al.
·
EBioMedicine
Show more works
View as search
Works count:
8
Citation count:
93
H-index:
4
I10-index:
2
Year
Topic
Type